Hutch News
New Science Spotlight Articles
Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
August 26, 2019
Colette Chaney named ‘2018 Nurse of the Year for Research Advancement’
March of Dimes Washington honors the longtime immunotherapy clinical research nurse
3 new projects map out immune responses to cancers
Scientists aim to gather knowledge that improves future immunotherapies
Fred Hutch at ASCO
Immunotherapy advances, insights into health economics and leadership awards dominate oncology gathering
3 big new leukemia research projects advance cutting-edge cell therapies, stem cell transplant
$20M renewal of 4-decade-long federal grant to Hutch scientists
Learning more from T-cell therapy trials
Fred Hutch Immunotherapy Integrated Research Center awards grants to Drs. Brian Till, Cameron Turtle
How new drugs become available to more patients
Filling in the unknowns on the balance between risk and benefit
10 highlights of Fred Hutch science in 2017
A look back at notable discoveries in cancer immunotherapy, HIV prevention and more
Donor MAIT cells take possession
From the Turtle and Fredricks Laboratories, Vaccine and Infectious Disease Division and Clinical Research Division
New insights into CAR T-cell therapy's potential side effects
<p>Detailed study of cytokine release syndrome and neurologic toxicities could help make emerging cancer immunotherapies safer</p>
First systematic study of infections after CAR T-cell therapy
“Benchmark” research could help reduce complications of emerging immunotherapy
Science without borders
At Fred Hutch and other U.S. research centers, a global village works to cure cancer and other diseases
Promising results in trial of engineered T cells in high-risk leukemia
High response rates to experimental immunotherapy in patients with treatment-resistant chronic lymphocytic leukemia
‘A place where miracles happen’: Opening of Bezos Family Immunotherapy Clinic highlights patient-focused science
Research symposium and ribbon cutting celebrates first-of-its-kind facility for experimental immunotherapies
Patients with advanced lymphoma in remission after T-cell therapy
New study: 7 of 11 trial participants who got two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission
Big takeaways from ASCO cancer conference: immunotherapy, precision medicine and more
Immunotherapy, precision medicine and patient-powered research among the highlights of the world’s largest cancer conference
Beyond immunotherapy: Xconomy forum covers breadth of Seattle’s life sciences scene
Xconomy forum highlights research in vaccines, organ transplants, big data, more
93 percent of advanced leukemia patients in remission after immunotherapy
‘Exciting’ but early results from trial of engineered immune cells
Dramatic remissions seen in immunotherapy trial of blood cancer patients
Experimental, living T-cell therapy shows promise for treating advanced disease, making immunotherapy a ‘pillar’ of cancer care
Many immunotherapy trial participants with blood cancer in remission, preliminary results show
High rates of complete remission reported in patients with advanced blood cancers in preliminary results from ongoing immunotherapy trial
Fred Hutch at ASCO
Research highlights from the annual meeting of the American Society of Clinical Oncology